ALK-Abelló

Regulatory Filings • Feb 3, 2014

Copenhagen, 2014-02-03 14:02 CET (GLOBE NEWSWIRE) --

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its grass
sublingual allergy immunotherapy tablet, which is licensed to Merck (known as
MSD outside the USA and Canada) for North America, has now been launched in
Canada.

Marketed in Europe under the brand name GRAZAX®, the product is known in Canada
as GRASTEK®.

The launch announcement follows regulatory approval from the Canadian
authorities of the New Drug Submission (NDS).

ALK’s President and CEO, Jens Bager, said: “This launch marks another major
step forward in globalising our portfolio of sublingual allergy immunotherapy
tablets. It also brings an effective new treatment option to grass allergy
sufferers in Canada.”

In Canada, GRASTEK® is indicated for treatment of grass pollen induced allergic
rhinitis (with or without conjunctivitis) in adults and children five years of
age and older. Across North America, an estimated 30 million adults and
children are estimated to suffer from grass pollen allergy.

                             ALK-Abelló A/S


                               Jens Bager
                        President & CEO

For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is the world leader in allergy
immunotherapy – a unique treatment of the underlying cause of allergy. The
company has approximately 1,800 employees with subsidiaries, production
facilities and distributors worldwide. ALK has entered into partnership
agreements with Merck and Torii to commercialise sublingual allergy
immunotherapy tablets in North America and Japan, respectively. The company is
headquartered in Hørsholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find
more information at www.alk.net.

About the partnership with Merck in North America
ALK has entered into a strategic partnership with Merck to develop, register
and commercialise a portfolio of sublingual allergy immunoterapy tablets
against grass pollen, ragweed and house dust mite allergy in the USA, Canada
and Mexico. Under the agreement, ALK will receive up to DKK 1.6 billion (USD
290 million) in milestone payments from Merck, of which, approximately DKK 300
million has already been recognised in the years 2007-13. In addition, ALK is
entitled to royalty payments on the net sales of the products on the North
American market as well as payments for product supply. Merck will be
responsible for all costs of clinical development, registration, marketing and
sales of the products on the North American markets. ALK will be responsible
for tablet production and supply.